HassaneMohamedZarourMD
Dermatology • Pittsburgh, PAProfessor, Medicine and Dermatology, University of Pittsburgh School of Medicine
Dr. Zarour is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
5117 Centre Ave
Research Pavilion, Suite 1.32a
Pittsburgh, PA 15213Phone+1 412-623-3272
Summary
- Dr. Hassane Zarour is a Pittsburgh-based dermatologist specializing in dermatology and cutaneous oncology. He completed his education in 1991 at the University of the Mediterranean Faculty of Medicine. His expertise includes skin cancers, melanoma, and the immunotherapy of cancer. Dr. Zarour has several publications, including studies on neoadjuvant therapies, tumor-infiltrating lymphocytes, and melanoma microbiota. He has participated in clinical trials involving advanced melanoma treatments, highlighting his focus on innovative approaches in melanoma management.
Education & Training
University of the Mediterranean Faculty of MedicineClass of 1991, Dermatology and Cutaneous Oncology
Certifications & Licensure
PA State Medical License 2003 - 2026
Clinical Trials
- CpG 7909/Montanide ISA 720 With or Without Cyclophosphamide in Combination Either With NY-ESO-1-derived Peptides or the NY-ESO-1 Protein for NY-ESO-1-expressing Tumors Start of enrollment: 2009 Jan 01
- NY-ESO-1 Vaccine in Combination With Ipilimumab in Patients With Unresectable or Metastatic Melanoma Start of enrollment: 2014 Jan 24
- Treatment of Advanced Melanoma With MK-3475 and Peginterferon Start of enrollment: 2014 Jul 24
Publications & Presentations
PubMed
- 2 citationsNeoadjuvant vidutolimod and nivolumab in high-risk resectable melanoma: A prospective phase II trial.Diwakar Davar, Robert M Morrison, Amiran K Dzutsev, Arivarasan Karunamurthy, Joe-Marc Chauvin
Cancer Cell. 2024-11-11 - 2 citationsAutomated Quantitative CD8+ Tumor-Infiltrating Lymphocytes and Tumor Mutation Burden as Independent Biomarkers in Melanoma Patients Receiving Front-Line Anti-PD-1 Immu...Dylan Fortman, Arivarasan Karunamurthy, Douglas Hartman, Hong Wang, Lindsey Seigh
The Oncologist. 2024-07-05 - 11 citationsMelanoma and microbiota: Current understanding and future directions.Bertrand Routy, Tanisha Jackson, Laura Mählmann, Christina K Baumgartner, Martin Blaser
Cancer Cell. 2024-01-08
Press Mentions
Combination Therapy Shows Promising Results in Treating Stage 3 MelanomaOctober 31st, 2024- Fecal Microbiota Transplants May Improve Resistance to Melanoma ImmunotherapyOctober 13th, 2021
- Fecal Microbiota Transplant Changes Melanoma Immunotherapy Non-Responders to RespondersFebruary 5th, 2021
- Join now to see all
Grant Support
- Reversing Melanoma-Induced T Cell DysfunctionNational Cancer Institute2011–2012
- Optimization Of Melanoma Vaccines With T-Helper EpitopesNational Cancer Institute2009–2012
- Melanoma Vaccines With Peptides, Protein And AdjuvantNational Cancer Institute2005–2009
- Optimization Of Melanoma Vaccine With T Helper EpitopeNational Cancer Institute2002–2007
- Promune W/Wo Chemo Trtmt Stage III B/C/Iv MelanomaNational Center For Research Resources2005
- Pilot Immun W/Cpg 7909 Or Multi-Epitope Immunogen Nyeso-1National Center For Research Resources2005
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
